Chemotherapy and immunotherapy before surgery for esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a combination of two chemotherapy drugs (paclitaxel and cisplatin) plus an immunotherapy drug (sintilimab) given before surgery for esophageal cancer. The goal is to see if this approach shrinks the tumor and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of esophageal cancer called squamous cell carcinoma, confirmed by biopsy.
- Your cancer is still in the chest area and can be removed with surgery (stages T1b-2N1-3 or T2-3N0).
- You have not had any previous cancer treatment like chemotherapy, radiation, or immunotherapy.
- You are in good overall health (able to do daily activities without much help).
- You have at least one tumor that can be measured on a scan.
- You have adequate organ function (heart, liver, kidneys, blood cells).
- You are willing to use effective birth control during the study and for up to 180 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a combination of chemotherapy, radiation, and an immunotherapy drug (cadonilumab) before surgery can help shrink esophageal cancer and improve outcomes. It is for people with a specific type of esophageal cancer that has not spread to other parts of the body.
This trial tests whether giving a combination of immunotherapy and chemotherapy before surgery can shrink esophageal cancer and improve outcomes. It is designed for patients with early-stage but treatable esophageal squamous cell carcinoma who are candidates for surgery.
This trial tests a combination of low-dose radiation, chemotherapy, and immunotherapy before surgery for esophageal cancer. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (camrelizumab), chemotherapy, and another targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor before it is removed, potentially improving outcomes.
This trial tests a combination of two targeted drugs (nimotuzumab and camrelizumab) plus standard chemotherapy before surgery for people with esophageal squamous cell carcinoma. The goal is to see if this approach helps shrink the tumor and improve outcomes.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.